Skip to main content

Table 1 Patient characteristics included in the study

From: rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy

Feature

No rhG-CSF (n = 61)

rhG-CSF (n = 246)

P value

Age, y

56.52 ± 10.22

57.74 ± 8.13

0.25

Weight, Kg

60.85 ± 10.80

59.40 ± 9.51

0.30

Gender, n (%)

  

0.97

 Male

46 (75.41%)

186 (75.61%)

 

 Female

15 (24.59%)

60 (24.39%)

 

Smoking, n (%)

  

0.96

 Never

24 (39.34%)

96 (39.02%)

 

 Former/current

37 (60.66%)

150 (60.98%)

 

Histopathology, n (%)

  

0.96

 Adenocarcinoma

29 (47.54%)

122 (49.59%)

 

 Squamous carcinoma

29 (47.54%)

112 (45.53%)

 

 Othersa

3 (4.92%)

12 (4.88%)

 

Differentiation, n (%)

  

0.32

 I

2 (3.28%)

7 (2.85%)

 

 II

7 (11.48%)

52 (21.14%)

 

 III

7 (11.48%)

33 (13.41%)

 

 NA

45 (73.77%)

154 (62.60%)

 

Clinical stage, n (%)

  

0.152

 IB

17 (27.87%)

43 (17.48%)

 

 IIA

2 (3.28%)

14 (5.69%)

 

 IIB

28 (45.90%)

97 (39.43%)

 

 IIIA

12 (19.67%)

78 (31.71%)

 

 IIIB

2 (3.28%)

14 (5.69%)

 

Chemotherapy, n (%)

  

0.24

 Taxane+Platinum

28 (45.90%)

101 (41.06%)

 

 Gemcitabine+Platinum

10 (16.39%)

55 (22.36%)

 

 Pemetrexed+Platinum

21 (34.43%)

87 (35.37%)

 

 Taxane

1 (1.64%)

1 (0.41%)

 

 Pemetrexed

1 (1.64%)

0 (0.00%)

 

 Othersb

0 (0.00%)

2 (0.81%)

 

No. of chemotherapy, n (%)

  

0.01

 < 4

28 (45.90%)

72 (29.27%)

 

 ≥ 4

33 (54.10%)

174 (70.73%)

 

Myelosuppression, n (%)

  

< 0.001

 0

56 (91.80%)

107 (43.50%)

 

 1

2 (3.28%)

55 (22.36%)

 

 2

2 (3.28%)

49 (19.92%)

 

 3

0 (0.00%)

20 (8.13%)

 

 4

1 (1.64%)

15 (6.10%)

 

Fever, n (%)

  

0.30

 No

58 (95.08%)

224 (91.06%)

 

 Yes

3 (4.92%)

22 (8.94%)

 

Antibiotic, n (%)

  

0.64

 No

56 (91.80%)

221 (89.84%)

 

 Yes

5 (8.20%)

25 (10.16%)

 

Complications, n (%)

  

0.90

 No

40 (65.57%)

167 (67.89%)

 

 Hypertension

9 (14.75%)

31 (12.60%)

 

 Tuberculosis

2 (3.28%)

5 (2.03%)

 

 Gastritis/Ulcers

3 (4.92%)

14 (5.69%)

 

 Hepatitis

0 (0.00%)

9 (3.66%)

 

 Diabetes

1 (1.64%)

5 (2.03%)

 

 Gallbladder disease

2 (3.28%)

3 (1.22%)

 

 Enteropatia

1 (1.64%)

2 (0.81%)

 

 Thyroid disease

1 (1.64%)

3 (1.22%)

 

 Coronary heart disease

1 (1.64%)

2 (0.81%)

 

 Chronic bronchitis/COPD

1 (1.64%)

5 (2.03%)

 
  1. Values are n (%) or mean ± SD
  2. No. Number, NA Not available, rhG-CSF Recombinant human granulocyte-colony stimulating factor, COPD Chronic obstructive pulmonary disease
  3. aOthers: large cell neuroendocrine carcinoma, atypical carcinoid, adenosquamous carcinoma, lymphoepithelioma-like carcinoma, large cell carcinoma, pulmonary blastoma
  4. bOthers: Irinotecan+Platinum, Etoposide+Platinum